|
Overview
Revance Therapeutics, Inc. (“Revance”) is a specialty biopharmaceutical company formed to discover, develop and commercialize novel biopharmaceuticals to treat skin and improve personal well-being. Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis. Revance is based in Mountain View, CA and is backed by a blue chip roster of healthcare venture capital investors, including Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures and Palo Alto Investors. The company’s two lead aesthetic products are:
We welcome you to our company website and invite you to contact us should you desire more information on our company or products.
|